

**Scientific Program:** \*For sponsored program, [prior registration is needed.](#)"

### Special program.

#### ISTH educational Program

- **ISTH educational program I: Day 1 (5/28), 16:00 – 18:00, Room 4**

"Risk factors and prevention of thrombosis" (WTD steering committee event)

Chairs: Eriko Morishita (Japan), Jean Connors (USA)

1. A Global survey for the World Thrombosis Day 2025. Marcello Di Nisio (Italy)
2. Tentative Plan for Therapeutic Guideline on Hereditary Thrombotic disorders. Beverley Hunt (UK)
3. Cancer associated thrombosis. Dr. Masataka Ikeda (Japan)

\* Zoom webinar link for viewing the satellite sessions is [here](#).

- **ISTH educational program II: Day 2 (5/29), 15:30 – 18:00, Room 4**

"Congenital and acquired hemorrhagic disorders"

Chairs: Teruto Hashiguchi, Tetsumei Urano (Japan)

1. Recent advances in Hemophilia therapy. Keiji Nogami (Japan)
2. Immune thrombocytopenia (ITP). Hisashi Kato (Japan)
3. Laboratory and clinical aspects of Factor XI deficiency. Chee We Tan (Australia)
4. Acquired FXIII deficiency. Teruto Hashiguchi (Japan)
5. Rare bleeding disorders due to hyperfibrinolysis: PAI-1 deficiency & TM/TAFI abnormality. Tetsu Urano (Japan)

\* Zoom webinar link for viewing the satellite sessions is [here](#).

#### APSTH 2026 Educational Program

- **Program I: Day 1 (5/28), 11:30-13:00, Event Space**

Chairs: Yukio Ozaki & Satoshi Fujii (Japan)

1. Welcome message from APSTH2026 Presidents. Tetsumei Urano & Teruto Hashiguchi (Japan)
2. APSTH and its regional role: challenges and opportunities. Satoshi Fujii (Japan)
3. Understanding hemostasis. Jameela Sathar (Malaysia)
4. Coagulation and hemostasis testing. Chee Wee Tan (Australia)

\* Zoom webinar link for viewing the satellite sessions is [here](#).

- **Program II: Day 2 (5/29), 9:00-10:30, Event Space**

#### Early career forum

Facilitators: Azusa Nagao, Kazuya Sakai, Teruto Hashiguchi, Tetsumei Urano (Japan)

Keynote Speech (10 min. each)

1. Preparing for a Career in Thrombosis and Hemostasis: The world has become much smaller. Spero Cataland (USA)
2. Advocacy and changing governmental and/or health service policy. Beverley Hunt (UK)
3. Standing on the Shoulders of Giants: My Journey Through TTP Research. Kazuya Sakai (Japan)
4. How to Balance Research, Career, and Parenting. Azusa Nagao (Japan)
5. open forum (50 min.)

\* Zoom webinar link for viewing the satellite sessions is [here](#).

- **Program III: Day 3 (5/30), 9:00-11:00, Event Space**

Chairs: Ng Heng Joo (Singapore) & Soo-Mee Bang (Korea)

1. Approach to thrombosis and thrombophilia. Ng Heng Joo (Singapore)

2. Management of anticoagulation in women. Lee Lai Heng (Singapore)
3. How to approach patients with bleeding tendency. Munekazu Yamakuchi (Japan)
4. Measuring Success: Outcome Assessment for Novel Hemophilia Therapies. Sheng-Chieh Chou (Taiwan)

\* Zoom webinar link for viewing the satellite sessions is [here](#).

### **JSTH/APSTH Joint Symposium Day 1 (5/28) 9:20-11:20, Room 3**

Chairs: Tsukasa Ohmori, Keiji Nogami, Teruto Hashiguchi (Japan)

1. Pathogenic Alterations in CD4+ T and B Cells in Acquired Hemophilia A via scRNA-seq. Enhao Li, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, China
2. Engineering platelets with Dab2 expression for efficient hemostasis in thrombocytopenia. Ching-Ping Tseng, 1Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Children's Medical Center, Taichung Veterans General Hospital, Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Department of Medical Laboratory Science and Biotechnology, China Medical University, Taiwan
3. Novel alternatively spliced human Protein Z isoform with predicted coagulation relevance. Sayeed ur Rehman Abul Kalam, Department of Biochemistry, Jamia Hamdard, India
4. Therapeutic Base Editing to Generate a Gain-of-function F9 variant for Hemophilia B. Nemekhbayar Baatarsogt, Department of Biochemistry, Center for Gene Therapy Research, Jichi Medical University, Tochigi, Japan
5. Factor XI localization in human deep venous thrombus and function of activated factor XI on venous thrombus formation and hemostasis. Nobuyuki Oguri, Department of Pathology, Faculty of medicine, University of Miyazaki, Department of Diagnostic Pathology, Miyazaki Medical Association Hospital, Japan
6. Molecular Analysis of a Novel FVIII Variant (FVIII-Nara) Identified in a Patient with Moderate Hemophilia A. Shoko Furukawa, Department of Pediatrics, Nara Medical University, Division of Hemophilia, Osaka National Hospital, Japan

### **Sponsored seminars** (Prior registration is needed)

#### **Luncheon seminars**

- **Day 1 (5/28) 13:00-13:50**

**LS1:** Room 4 [Registration](#) available here

Acquired Hemophilia and NovoSeven®: Time to Update a Long-Standing Therapeutic Choice

Chair: Dr. Teruto Hashiguchi (Kagoshima University Director and Vice President)

Speaker: Dr. Keiji Nogami (Department of Pediatrics, Nara Medical University Professor)

Novo Nordisk Pharma Ltd.

**LS2:** Room 5 [Registration](#) available here

Pitfalls in Diagnosing TTP: Lessons from Atypical Presentations

Chair: Dr. Masataka Ishimura (Department of pediatrics, graduate of medical sciences, Kyushu University Japan)

Speaker: Dr. Kazuya Sakai (Nara Medical University, Department of Transfusion Medicine, Japan)

Takeda Pharmaceutical Company Limited

## Day 2 13:30-14:20

**LS3:** Room 4 [Registration](#) available here

The Changing Landscape of TTP Management

Chair: Dr. Masanori Matsumoto (Department of Hematology and Blood Transfusion Medicine, Nara Medical University)

Speaker: Dr. Spero Cataland (Division of Hematology, Department of Internal Medicine, Ohio State University Medical Center)

Sanofi K.K.

## Day 3 13:30-14:20

**LS4:** Room 3 [Registration](#) available here

The Eight Year Journey of Emicizumab: Evidence from Bench to Bedside

Chair: Dr. Rie Shirayama (University of Occupational and Environmental Health)

Speaker: Dr. Zenjiro Sampei (Chugai Pharmaceutical Co., Ltd.) / Ryuui Miyashita (Tokyo Medical University / Clinical Laboratory Medicine)

Chugai Pharmaceutical Co., Ltd.

## Sweet's seminar

### Day 1 15:00-15:50

**SS1:** Room 5 [Registration](#) available here

Impact of EHL-FIX and Evolving Patient Needs in Hemophilia B in Japan

Chair: Dr. Yeu-Chin Chen (Hemophilia Care & Research Center, Tri-Service General Hospital)

Speaker: Dr. Ei Kinai (Department of Laboratory Medicine, Tokyo Medical University)

CSL Behring K.K.

## General scientific program

### Oral sessions 1-9

#### Day 1 (5/28) afternoon

##### 1. Venous thrombosis 14:00-15:00, Room 3

Chairs: Lai Heng Lee (Singapore) & Jameela Sathar (Malaysia)

[Abstracts available here](#)

1. Automatic Segmentation and Quantification of Cerebral Venous Thrombus. Xiao xu Yang (China)

2. Association of markers of coagulation, fibrinolysis and inflammation with PTS. Worapapas Chalerm suwiwattanakan (Thailand)

3. Long COVID alopecia: inflammation, coagulation and fibrinolysis, and keratinocyte injury. Satomi Nagaya (Japan)

4. Paediatric Thrombosis: A Three-Year Malaysian Tertiary Centre Experience. Liana Yusof (Malaysia)

5. Prediction Risk factors for portal vein thrombosis and time to portal hypertension. Patcharee Komvilaisak (Thailand)

##### 2. Hemophilia I 14:00-15:00, Room 4

Chairs: Shyh-Shin Chiou (Taiwan) & Keiji Nogami (Japan)

[Abstracts available here](#)

1. Noninversion Variants in Sporadic Hemophilia A: An Origin, Inheritance and Timing Study. Shih-Yao Lin (Taiwan)

2. Utility of Next-Generation Sequencing in the Genetic Diagnosis of Hemophilia. Chepsy Philip (India)
3. Pre-existing Neutralizing Antibodies to AAV3B, AAV5, and AAV8 in Mongolian Hemophilia. Nemekhbayar Baatartsogt (Japan)
4. Monitoring Optimization for Efanesoctocog Alfa. Te-Fu Weng (Taiwan)
5. Inhibitor Development in Severe Hemophilia: Patterns Across Exposure Days. AKSHAY MIDDINTI (India)

**3. Pathogenesis I 14:00-15:00, Room 5**

Chairs: Shuhwa Lin (Taiwan) & Tsukasa Ohmori (Japan)

[Abstracts available here](#)

1. Characterization and Regenerative Efficacy of Platelet-Rich Plasma-Derived Exosomes. Soo chong Kim (Japan)
2. Basic Study on VWF Induced by Low-Dose Colchicine in Vascular Endothelial Cells. Akito Tabaru (Japan)
3. Thrombomodulin enhances tumor progress via ezrin- and FAK-dependent cancer cell plasticity. Cheng-Hsiang Kuo (Taiwan)
4. Thrombomodulin as a Multi-Domain Regulator of Neovascularization. Hua-Lin Wu (Taiwan)

**4. Arterial diseases 15:00-16:00, Room 4**

Chairs: Raymond Wong (Hong Kong) & Jiaan-Der Wang (Taiwan)

[Abstracts available here](#)

1. The role of CD93 in abdominal aortic aneurysm. Chao-Han Lai (Taiwan)
2. Whole Blood Viscosity in Ischemic Heart Disease: Single-Center Pilot Investigation. Jung Rae Cho (Republic of Korea)
3. Erythrocytosis is associated with cardiovascular disease: The Shizuoka Study. Aya Shoji-Asahina (Japan)
4. Transplant-associated thrombotic microangiopathy (TA-TMA) treated with eculizumab. Taichiro Tokura (Japan)
5. OACs to Prevent Stroke in AF Patients After Prior Intracranial Hemorrhage: Meta-analysis. Mohamed Hamouda Elkasaby (Egypt)

**Day 2 (5/29) afternoon**

**5. Platelets 14:30-15:30, Room 4**

Chairs: Yukio Ozaki (Japan) & Joyce Lam (Singapore)

[Abstracts available here](#)

1. Antiplatelet effects of spironolactone through regulation of thromboxane A2 generation. Seong mo Yang (Republic of Korea)
2. Refractory ITP Revisited: MYH9-Related Disorder with Multisystem Involvement. Wan Alina Khadijah Wan Nik Ahmad Mustafa (Malaysia)
3. Efficacy of Low-Dose Rituximab in Patients with Immune Thrombocytopenia: A Meta-Analysis. April Joy Ong (Philippines)
4. Platelet Dysfunction Due to CalDAG-GEFI Abnormalities. Tsuyoshi Kojo (Japan)
5. Autoimmune acquired factor XI deficiency with incomplete FXI recovery.

Sadayuki Higashi (Japan)

**Day 3 (5/30) afternoon**

**6. Hemophilia II 14:20-15:20, Room 3**

Chairs: Chee Wee Tan (Australia) & Soo-Mee Bang (Korea)

[Abstracts available here](#)

1. The Outcomes of Acquired Hemophilia A in Singapore: A Retrospective Cohort Study. Sz-Ying Lee (Singapore)
2. Efficacy of Low-Dose Efficizumab Prophylaxis in Hemophilia A: A Meta-Analysis. April Joy Ong (Philippines)
3. Current Epidemiology and Treatment of Hemophilia in Taiwan: A Multicenter Survey. Chia-Yau Chang (Taiwan)
4. Acceptance and Effectiveness of Online Exercise on Joint Health and ROM in Hemophilia. GEETA SURI SHARMA (India)

**7. Pathogenesis II 14:20-15:20, Room 4**

Chairs: Heng Joo Ng (Singapore) & Munekazu Yamakuchi (Japan)

[Abstracts available here](#)

1. Disulfide bond status modulates autoantibody recognition in antiphospholipid syndrome. Mark Schreuder (Australia)
2. Deletion of platelet STK10 impairs deep vein thrombus formation. Ping Fu (China)
3. CD248 Deficiency Accelerates VSMC Loss and Aortic Degeneration in Experimental AAA. Tai-Tzu Hsieh (Taiwan)
4. Differential mRNA dynamics of antithrombin in nonsense, frameshift variants. Ibuki Yasuda (Japan)
5. Functional Characterization of PROC Variants Triggering Nonsense-mediated mRNA Decay. Yurika Yamaguchi (Japan)

**8. Diagnosis 15:30-16:30, Room 3**

Chairs: Satoshi Fujii (Japan) & Katsue Suzuki-Inoue (Japan)

[Abstracts available here](#)

1. Prospective Validation of a Rule-Based Screening Tool using CWA for Acquired Hemophilia. Jing Yuan Tan (Singapore)
2. Circulating Biomarkers Associated With Atrial Reverse Remodeling. Hiroshi Kasabata (Japan)
3. Quantitative Lupus Anticoagulant Assay: Risk Stratification for Antiphospholipid Syndrome. Yuta Inoue (Japan)
4. dRVVT Ratio Cutoff for Identifying Triple-Positive Antiphospholipid Profiles. Yi Hua Low (Singapore)
5. Early fibrin monomer levels predict hemorrhagic progression and mortality in severe TBI. Van Khang Thach (Viet Nam)

**9. Therapeutic 16:30-17:30, Room 3**

Chairs: Dong-Tsamn Lin (Taiwan) & Tetsumei Urano (Japan)

[Abstracts available here](#)

1. Clinical Manifestations in the Prospective Cohort of the Korean Bleeding Disorder Registry. Jung Woo Han (Republic of Korea)
2. Iron Therapy and Thrombotic Outcomes in CKD: A Systematic Review and Meta-analysis. Caryn Louise Gutierrez (Philippines)
3. Bleeding and Mortality Outcomes of Warfarin vs DOAC Emergency Reversal in an Asian Cohort. Hock Peng Koh (Malaysia)
4. VTE in Japanese Patients with Lymphoma: Incidence and Clinical Utility of Scores. Sumire Inoue (Japan)
5. DOACs in Pediatric Congenital and Acquired Heart Disease: Meta-Analysis. Mohamed Hamouda Elkasaby (Egypt)

### Poster Sessions I & II, Event Space

Poster session I Day 1 (5/28) - Day 2 (5/29) (poster manning Day 2 (5/29) 12:00-13:00)

[Abstracts available here](#)

#### 1. Hemophilia

P1-1 Withdrawn

P1-2 VTE in Japanese Patients with Lymphoma: Incidence and Clinical Utility of Scores. Hyeon Woo Bang (Japan)

P1-3 Long COVID alopecia: inflammation, coagulation and fibrinolysis, and keratinocyte injury. Hyeon Woo Bang (Japan)

P1-4 Genetic Variants in a Type 1 VWD patient with Reduced VWF and Heterozygous Deletion. Yen-Ting Chang (Taiwan)

P1-5 Presentation at Oral Session

P1-6 Withdrawn

P1-7 The Acquired Factor V Inhibitor: A Rare and Challenging Encounter. Rathiga Krishnamani (Malaysia)

P1-8 Acquired Factor XI Deficiency Following Living Donor Liver Transplantation – A case study. Sara Ali Zaidi (Pakistan)

P1-9 Perioperative Management in a Patient with Severe Hemophilia A and Infective Endocarditis. JIAAN-DER WANG (Taiwan)

P1-10 Haemophilia in Sarawak, Malaysia: A Registry Study of Clinical and Treatment Characteristics. Grace Wan Chieng Lee (Malaysia)

P1-11 A Case Report on Chronic Myeloid Leukemia in a patient with Severe hemophilia A. Joseph Emmanuelle Siatan (Philippines)

P1-12 The Hidden Bleeder: Acquired Haemophilia A Masquerading as Deep Vein Thrombosis (DVT). FATIN AKMAL BAHAROM (Malaysia)

P1-13 Safe Surgery for Hemophilic Pseudotumour on Emicizumab in Resource-Limited Settings. Khant Zwe Aung (Myanmar)

P1-14 Beyond the isolated prolonged aPTT: Why Comprehensive Coagulation Screening Matters. Elyn Syazana Zolkifli (Malaysia)

P1-15 Massive Hemophilic Pseudotumor with Inhibitor Treated with Continuous Factor Infusion. Vielle Sinfuego (Philippines)

P1-16 Low Dose Emicizumab and BPA in Knee Arthroplasty of a Severe Hemophiliac with Inhibitor. Ma Angelina Mirasol (Philippines)

P1-17 Withdrawn

P1-18 Bloodless arthroplasty surgery in patients with bleeding disorders. Yee Yee Yap

(Malaysia)

P1-19 Hemophilic Pseudotumor in a 48 Male with High Titer Inhibitor: A Collaborative Success. Ma Angelina Mirasol (Philippines)

## **2. Bleeding**

P2-1 Enhancing the storage quality and shelf life of Platelet Concentrates Using SSP+ PAS. BARANIDHARAN G R (India)

P2-2 COAGULATION FACTOR XIII DEFICIENCY FOLLOWING KIDNEY TRANSPLANTATION: A CASE REPORT. Hoai Nam Nguyen (Viet Nam)

P2-3 Hidden Factor X Deficiency Amid Anticoagulant-Associated Bleeding. May Anne Cheong (Singapore)

P2-4 Spontaneous Spinal Epidural Hematoma as Initial Manifestation of JAK2-Positive MPN. Francien Bonifacia Lumauag (Philippines)

P2-5 Managing GI Bleeding in a Child with Glanzmann Thrombasthenia Without Platelets. Joyce Lam (Singapore)

P2-6 Vitamin K-Dependent Factor Deficiency from Herbal Medicine: Case Series. Yin Man Lim (Malaysia)

P2-7 Multiple Myeloma Manifesting with Acute Spontaneous Bleeding: A Case Report. Emmanuel Enrique Manlutac (Philippines)

P2-8 ED Management of Anticoagulant-Related Bleeding: An Educational Review. Mohamad Hamim Mohamad Hanifah (Malaysia)

## **3. New strategies (laboratory test)**

P3-1 Re-assessing the laboratory's criteria for identification of clotted samples for APTT. Wei Jian, Daniel Hong (Singapore)

P3-2 Performance and sensitivity profile of Coagpia™ APTT-F on the CP3000™. Hirohito Hashinokuchi (Japan)

P3-3 Perioperative Blood Management in Cardiac Surgery Guided by Rotational Thromboelastometry. Isabel Rodríguez Martín (Spain)

P3-4 Antiphospholipid Syndrome Testing: Limitations and the Need for Multiparameter Diagnosis. Raja Ruzanna Raja Abdul Aziz (Malaysia)

P3-5 Reference intervals for adjusted APTT clot waveform analysis (CWA) using Sysmex CN3000. Wan Hui Wong (Singapore)

P3-6 Pneumatic tube transport affects platelet aggregation depending on the type of agonist. Wenshan Liu (Singapore)

P3-7 Pre-Analytical Challenges in ADAMTS-13 Testing for Suspected TTP: Ampang Hospital Experience. Amira Aina Binti Mohamad Jasmadi (Malaysia)

P3-8 Effect of hemolysis on PT, APTT and Clot Waveform Analysis parameters. Yvonne Chu (Singapore)

Poster session II Day 2 (5/29)- Day 3 (5/30) (poster manning Day 3 (5/30) 12:45-13:30)

[Abstracts available here](#)

## **4. Thrombosis**

P4-1 Withdrawn

P4-2 Presentation at Oral Session

P4-3 Presentation at Oral Session

P4-4 VTE in Japanese Patients with Lymphoma: Incidence and Clinical Utility of Scores. Soo-Mee Bang (Japan)

P4-5 Incidence of Venous Thromboembolism: The 4th Korean Nationwide Study. Soo-

Mee Bang (Republic of Korea)

P4-6 Increased Venous Thromboembolism (VTE) in hospitalized patients with Metabolic Syndrome. Lai heng Lee (Singapore)

P4-7 Withdrawn

P4-8 KNOWLEDGE, ATTITUDE AND PRACTICES OF PHYSICIANS AND NURSES ON VENOUS THROMBOEMBOLISM. Andrea Nicole Perez (Philippines)

P4-9 Affordability of DOACs for Cancer-Associated Thrombosis in Upper-Middle-Income Countries. Devi Amelia (Indonesia)

P4-10 Budd-Chiari in TAFRO iMCD: A Rare Thrombotic Complication of Hyperinflammation. Janika Adrienne Balane (Philippines)

P4-11 The extended anticoagulation for cancer associated thrombosis: A Systematic review. Andree Kurniawan (Indonesia)

P4-12 Clonal Hypereosinophilic Syndrome Presenting as Chronic Upper Limb Ischemia, A Case Report. Erlinda Cruz (Philippines)

P4-13 Laboratory Diagnosis of Thrombotic and Hemostatic Disorders: An Educational Review. Jubaida Paraja (Malaysia)

## **5. TTP**

P5-1 Clinical Course of Thrombotic Thrombocytopenic Purpura in Young Adults with Lupus. April Joy Ong (Philippines)

P5-2 Withdrawn

## **6. Coagulation, fibrinolysis & platelets**

P6-1 Naringin modulates PCI to enhance thrombin and APC inhibition in coagulation pathways. Urfi Siddiqui (India)

P6-2 Cell-type specific increase of coagulation factors in mouse models with liver hyperplasia. Mo-Chu Fang (Taiwan)

P6-3 Refractory Immune Thrombocytopenia in Pregnancy Managed with Laparoscopic Splenectomy. Ernest Matthew Paggabao (Philippines)

P6-4 Association of Integrin Gene Variants with Primary Ovarian Insufficiency in Korean Women. DA HWAN KIM (Republic of Korea)

P6-5 A Rare Case of Asymptomatic Combined Factor XI and XII Deficiency in a Filipino Woman. Michelle Angelique Parreñas (Philippines)

## **7. New strategies (therapy)**

P7-1 Withdrawn

P7-2 Aspirin versus Clopidogrel Monotherapy in the Chronic Phase After Carotid Artery Stenting. Jun Young Chang (Republic of Korea)

P7-3 Astaxanthin Inhibits Thrombosis by Reducing Both Platelet Activation and Blood Coagulation. Chao Fang (China)

P7-4 Novel nanoparticulate carrier for oral delivery of low molecular weight heparin. Saurabh Bhargava (India)

P7-5 Preparation and Characterization of Nanocarriers for Transdermal Delivery of Enoxaparin. Mani Bhargava (India)

P7-6 Transplant-associated thrombotic microangiopathy (TA-TMA) treated with eculizumab. Taichiro Tokura (Japan)

P7-7 Novel Charcoal-based Adsorbents for DOAC Removal: Enhancing Lupus Anticoagulant Diagnosis. Hyerim Kim (Republic of Korea)

P7-8 In-vivo evaluation of TMC nanoparticles for oral delivery of low molecular weight heparin. Varun Bhargava (India)

P7-9 Polyelectrolyte Nanoparticles for Oral Delivery of Low Molecular Weight Heparin.  
Riya Bhargava (India)

P7-10 Factor XI/XIa Inhibitors for Thrombosis: A Systematic Review and Meta-Analysis. Dimas Priantono (Indonesia)

P7-11 Vitamin K in the ICU: A Systematic Review and Meta-Analysis of Bleeding and Thrombosis. Caryn Louise Gutierrez (Philippines)

P7-12 Statin Exposure and Mortality in Multiple Myeloma: A Systematic Review and Meta-Analysis. CARYN LOUISE GUTIERREZ (Philippines)

P7-13 Low-Dose Subcutaneous Protein C Concentrate in a Child with absent Protein C. Yee Yee Yap (Malaysia)

P7-14 Preoperative anticoagulant in atrial myxoma-associated acute ischemic stroke.  
Andree Kurniawan (Indonesia)